The increasing complexity of malignant diseases treatment necessitates a thorough understanding of varied healthcare models. This article aims to investigate the strengths and limitations of transatlantic cancer care, comparing the clinical pathways in both the United States and other regions. Through a systemic lens, we will review key variables,